Pivotal bioVenturePartners China’s portfolio OncXerna Therapeutics ranks as Top 5 among 479 global precision medicine startups & scaleups, published by StartUS Insights recently.

GlobalStartup Heat Map: 5 Top Precision Medicine Startups

The 5 precision medicine startups below are chosen based on StartUs’s data-driven startup scouting approach, taking into account factors such as location, founding year, and relevance of technology, among others. This analysis is based on the Big Data & Artificial Intelligence (AI)-powered StartUs Insights Discovery Platform, covering over 1.3 million startups & scaleups globally.

OncXerna develops an AI-based Ribonucleic Acid (RNA) Platform
The research and development to find a cure for cancer has been an ongoing challenge for the medical field resulting in continuous improvements in cancer treatments. One of the directions in cancer treatment research is to analyze cancer-causing mutations in the genome. Startups and scaleups are developing research platforms and techniques to better understand the underlying causes of cancer.

US-America startup OncXerna develops an RNA expression biomarker panel (TME Panel-1) that is specific to the tumor microenvironment (TME). The solution allows clinical researchers to develop algorithms for effective treatment using RNA signature derived from biomarker panels. The solution aims to match the patient to the treatment rather than generalizing treatments for the whole population.

Other fourcompanies are Perceiv AI, Precomb Therapeutics, AUM Biosciences and AceTech. Details can be found with bottom source links .  

About OncXerna Therapeutics
OncXerna Therapeutics is a clinical stage oncology company developing novel monoclonal antibodies to treat solid tumors. In combination with its innovative precision medicine platform, the Xerna TME Panel, OncXerna leverages artificial intelligence technologies and RNA expression-based biomarkers to match a specific patient’s tumor with the drugs best suited to treat that tumor. Our current clinical pipeline includes the company’s lead product candidate, Navicixizumab, which is a bispecific antibody that targets both VEGF and DLL4 to treat solid tumors and is currently entering a Phase 2/3 study for the treatment of ovarian cancer. By integrating our novel Xerna TME Platform with our deep expertise in clinical development, we believe we can accelerate the development, approval and commercialization of drug product candidates and bring meaningful new treatments to patients at an earlier point in time in their disease progression. For more information, please visit oncxerna.com, or follow us on LinkedIn and Twitter.

About Pivotal bioVenture Partners China
Pivotal bioVenture Partners China, belongs to Nanfeng Life Science Co., LTD. (Nanfeng Life Science), which focuses on global life science investment under Hong Kong Nanfeng Group. DFSC capital is committed to finding innovative products and technologies worldwide and creating a number of leading biomedical enterprises in the Greater China region to meet the growing global market, especially the medical needs of the Chinese market. Dingfeng Shengke capital investment covers biopharmaceutical, medical devices and medical services and other related fields. Our team is comprised of experienced life science investors and entrepreneurs with extensive industry experience in business creation and venture capital.
For more information, please visit https://www.pivotalbiovp.cn

Source:
https://www.startus-insights.com/innovators-guide/discover-5-top-precision-medicine-startups/